Fig. 3From: Identification and validation of an immune cell infiltrating score predicting survival in patients with lung adenocarcinomaa Survival analysis for patients (stage II–IV) with low scores stratified by the receipt of adjuvant chemotherapy in the training cohort (P = 0.909). b Survival analysis for patients (stage II–IV) with high scores stratified by the receipt of adjuvant chemotherapy in the training cohort (P = 0.764). c Survival analysis for patients (stage II–IV) with low scores stratified by the receipt of adjuvant chemotherapy in the validation cohort (P = 0.010). d Survival analysis for patients (stage II–IV) with high scores stratified by the receipt of adjuvant chemotherapy in the validation cohort (P = 0.213)Back to article page